Literature DB >> 21046490

Is there a link between angiotensin receptor blockers and cancer?

Frank Enseleit1, Frank Ruschitzka.   

Abstract

Entities:  

Year:  2011        PMID： 21046490     DOI： 10.1007/s11906-010-0162-y

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  12 in total

Review 1.  Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system.

Authors:  Bernard I Lévy
Journal:  Circulation       Date:  2004-01-06       Impact factor: 29.690

2.  Angiotensin-receptor blockers and cancer: urgent regulatory review needed.

Authors:  Steven E Nissen
Journal:  Lancet Oncol       Date:  2010-06-11       Impact factor: 41.316

Review 3.  The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous.

Authors:  Timothy L Reudelhuber
Journal:  Hypertension       Date:  2005-11-14       Impact factor: 10.190

4.  Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox.

Authors:  Martin H Strauss; Alistair S Hall
Journal:  Circulation       Date:  2006-08-22       Impact factor: 29.690

5.  Angiotensin receptor blockers: baseline therapy in hypertension?

Authors:  Franz H Messerli; Sripal Bangalore; Frank Ruschitzka
Journal:  Eur Heart J       Date:  2009-08-31       Impact factor: 29.983

6.  The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy.

Authors:  Angelo D'Amore; M Jane Black; Walter G Thomas
Journal:  Hypertension       Date:  2005-11-14       Impact factor: 10.190

Review 7.  How to explain the differences between renin angiotensin system modulators.

Authors:  Bernard I Levy
Journal:  Am J Hypertens       Date:  2005-09       Impact factor: 2.689

Review 8.  Angiotensin receptors: a new role in cancer?

Authors:  Frédérique Deshayes; Clara Nahmias
Journal:  Trends Endocrinol Metab       Date:  2005-09       Impact factor: 12.015

9.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

Authors:  Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren; Salim Yusuf; Stuart Pocock
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

10.  Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor.

Authors:  David R Soto-Pantoja; Jyotsana Menon; Patricia E Gallagher; E Ann Tallant
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.